Journal

What papers say about KPV

This shop does not claim what KPV does. The lines below come from papers opened for this note. Where a paper is reporting a mouse experiment, it is labeled as that paper's mouse experiment. This page does not turn any of it into a protocol, a dose, or medical advice.

KPV is the end of a longer hormone

Two papers opened here agree on the chemistry, in plain language.

Guillaume Dalmasso and colleagues, Gastroenterology, published online in 2007 and cited as the 2008 journal issue, write: "The tripeptide KPV (Lys-Pro-Val), which is the C-terminal sequence of α-melanocyte stimulating hormone (α-MSH)." Later they say it again: "KPV constitutes the three C-terminal amino acids of α-MSH." Lysine, proline, valine. Three residues. Not the whole hormone.

Thomas Luger and Thomas Brzoska, Annals of the Rheumatic Diseases, 2007, describe alpha-MSH itself as "a tridecapeptide derived from the proopiomelanocortin by post-translational processing." A tridecapeptide is thirteen amino acids. Their abstract says: "Most of the anti-inflammatory activities of α-MSH can be attributed to its C-terminal tripeptide KPV." That sentence is their review's judgment. This shop does not adopt it as a product claim.

The same review spends time on a different tripeptide, K(D)PT, in which valine is replaced by threonine. K(D)PT is not KPV. The vial on this shop is KPV.

Luger and Brzoska are also cautious about receptors. "Whether KPV and K(D)PT bind to MC-Rs and utilise the identical signalling pathways as the natural ligands is not yet clear. According to several binding studies, KPV seems not to bind to MC-1R and fails to increase cyclic adenosine monophosphate (cAMP) levels." MC-R means melanocortin receptor. Their "seems" is doing real work. It is a review of binding studies, not a new binding experiment in that paper.

Their abstract lists animal models in which anti-inflammatory effects of alpha-MSH, the parent hormone, have been studied: irritant and allergic contact dermatitis, cutaneous vasculitis, asthma, inflammatory bowel disease, rheumatoid arthritis, and ocular and brain inflammation. That list is about alpha-MSH. It is not reprinted here as a list of KPV results.

One KPV-specific line in that review is antimicrobial, and it is theirs: alpha-MSH "and its C-terminal tripeptide KPV have been discovered to exhibit antimicrobial activity against pathogens such as Staphylococcus aureus and Candida albicans." That is the review citing earlier work. It is not a test of the vial sold here.

What the cell experiments reported

The Dalmasso paper is the one that ties KPV to a transporter. The cells are human cell lines, not animals: intestinal epithelial lines, including Caco2-BBE and HT29-Cl.19A, and Jurkat T cells.

The abstract's result sentence is: "Nanomolar concentrations of KPV inhibit the activation of NF-κB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion. We found that KPV acts via hPepT1 expressed in immune and intestinal epithelial cells." PepT1 is a transporter that normally moves dipeptides and tripeptides. The authors' interest in it is that, in their earlier work, which they cite, the transporter is scarce in a healthy colon and present on epithelial cells in chronically inflamed colon, and also on some immune cells.

In the Caco2-BBE experiments they report, the cells expressed two melanocortin receptor isoforms, MC3R and MC5R. KPV did not raise intracellular cAMP. The authors read that as evidence that those receptors were not how KPV was acting in those cells. A competing PepT1 substrate, glycine-leucine, wiped out KPV's effect on NF-κB activation. In HT29-Cl.19A cells, which they say do not express PepT1, KPV did not reduce the inflammatory signals they measured. When that line was made to express PepT1, the effect appeared, and the competing substrate removed it again. Their discussion states the conclusion in one sentence: "We show that the anti-inflammatory effect of KPV is not melanocortin receptor-mediated but PepT1-mediated."

They also report a transport number. In Caco2-BBE cells, hPepT1 had a Km of about 160 micromolar for KPV. A Km is a measurement of transporter affinity in that cell experiment. It is not a dose, and this note will not use it as one.

The paper's own conclusion goes further than the measurements: "This study indicates that KPV is transported into cells by PepT1 and might be a new therapeutic agent for IBD." "Might" is the authors' word. Inflammatory bowel disease is their suggested direction. It is not an approved use, and it is not a claim this shop makes.

Mouse experiments in that paper

The same paper tested KPV in mice. The methods use female C57BL/6 mice and two ways of producing colitis: dextran sodium sulfate, and trinitrobenzene sulfonic acid. The abstract says "oral administration of KPV reduces the incidence of DSS-, and TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression." The discussion is more specific about what fell: loss of body weight, colonic myeloperoxidase activity, histological signs of inflammation, and pro-inflammatory cytokine mRNA. The authors call this the first report, in their words, of KPV-mediated reduction of colitis.

Those are that paper's mouse experiments. The amounts used to induce colitis, and the amount of KPV put in the drinking water, are not repeated here. An animal-experiment result is not a human schedule, and this page does not convert one into the other.

The KPV vial

KPV 10mg is one research vial. The price is $40. Purity is at least 99 percent. Fill is within 10 percent of the label, so a vial labeled 10mg is filled from 9mg to 11mg. Sale is to adults 21 and older. The material is for laboratory research. It is not for people or animals. This shop is not a pharmacy. This page is not medical advice.

KPV also appears as one labeled component inside the blend nicknamed KLOW. KLOW is not a new name for KPV. It is KPV plus other peptides in one vial. The single tripeptide is the vial linked above. KLOW is a separate listing.

The July 2026 vote is quoted on its own page

MedPage and Pharmacy Times printed the committee tallies. Those tallies, and the lines saying a recommendation is not an approval, are in The July 2026 peptide vote is not an FDA approval. This page does not turn that vote into a shop claim.

What CNN and the other outlets wrote

CNN's July 22 piece lists KPV "for wound healing and inflammatory conditions," and prints an 8-6 vote with one abstention for the forms the committee considered. CNN. Fox prints the same proposed use, "wound healing and inflammatory condition." Fox News. Scientific American says people claim KPV "reduces inflammation," and that adding it to BPC-157, TB-500, and GHK-Cu is what gets called "glow" or "KLOW." Scientific American. NPR includes KPV among six peptides the panel recommended for a compounding path that is still not an approval. NPR. The roundup is What CNN, Fox, and the other outlets wrote.

Sources

• Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology, 2008. Full text
• Luger TA, Brzoska T. α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases, 2007. Full text

Research vials. 21 and older. Not for people or animals.

Research vials. 21 and older. Not for people or animals. Not medical advice.